Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina

NEW YORK, May 22, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2807-100free.

--
InterMune  Inc.  Analyst  Notes
On May 18, 2014, InterMune Inc. (InterMune) informed that the results from the Phase III ASCEND study evaluating pirfenidone in patients with idiopathic pulmonary fibrosis were presented at the International Conference of the American Thoracic Society in San Diego, and published on-line in the New England Journal of Medicine. Dan Welch, Chairman, CEO and President of InterMune, said, "The presentation of the ASCEND results at ATS and publication in the New England Journal of Medicine represents an important milestone in the decade of clinical research we have conducted on pirfenidone. The study results provide strong evidence of pirfenidone's robust treatment effects and augment its already well-established safety and tolerability profile. We currently intend to resubmit the pirfenidone New Drug Application to the U.S. FDA in the coming weeks." InterMune's stock rallied 13.44% in the following day's trading session, May 19, 2014, ending trade at $38.92. The  full  analyst  notes  on  InterMune  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2807-ITMN-22May2014.pdf

--
Actavis  Plc  Analyst  Notes
On May 15, 2014, Actavis Plc (Actavis) announced that the Company has extended its exclusive agreement with Janssen Pharmaceuticals, Inc. (JPI), which is set to expire in December 31, 2014, to continue the supply of authorized generic version of JPI's Concerta. According to the terms of the renewed agreement, JPI will continue to manufacture and supply Actavis with all dosage strengths of the authorized generic product, and Actavis will continue to market and distribute the product in the U.S. In addition, Actavis informed that it may file an abbreviated new drug application (ANDA) for a generic version of Concerta with the U.S. Food and Drug Administration and may launch its own ANDA product at the conclusion of the exclusive supply agreement. The revenues from the sale of the drug will be divided equally among both the companies. The extended agreement is valid till December 31, 2017 The  full  analyst  notes  on  Actavis  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2807-ACT-22May2014.pdf

--
Bristol-Myers  Squibb  Co.  Analyst  Notes
On May 19, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) and AbbVie jointly announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab - an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. According to the Companies, the designation is based on findings from a randomized Phase II, open-label study that evaluated two dose levels of elotuzumab in combination with lenalidomide and low-dose dexamethasone in previously-treated patients, including the 10 mg/kg dose that is being studied in Phase III trials. Michael Giordano, Senior Vice President, Head of Development, Oncology & Immunosciences, Bristol-Myers, said, "This Breakthrough Therapy Designation underscores the potential of elotuzumab in this setting and reinforces Bristol-Myers Squibb's longstanding commitment to the research and development of novel medicines to treat hematologic malignancies." The  full  analyst  notes  on  Bristol-Myers  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2807-BMY-22May2014.pdf

--
AbbVie  Inc.  Analyst  Notes
On May 15, 2014, AbbVie Inc. (AbbVie) announced that it has named Michael Severino, M.D. as its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. In his new role, Mr. Severino will lead the R&D, Medical Affairs and Regulatory Affairs organizations at AbbVie. Further, Severino will bring insights and expertise from his career spanning genomics and development within the biotech industry. Prior to joining AbbVie, Severino, most recently, served as the Senior Vice President and Chief Medical Officer, at Amgen. Commenting on the appointment, Richard A. Gonzalez, Chairman and CEO, AbbVie, said, "We are fortunate to have a leader of his caliber to steer our efforts to develop treatments for today's toughest health challenges. He will be instrumental in moving our pipeline and strategy forward." The  full  analyst  notes  on  AbbVie  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2807-ABBV-22May2014.pdf

--
Illumina  Inc.  Analyst  Notes
Illumina Inc. (Illumina) posted on the Events Details section of its official website that the Company will host its Annual Shareholder Meeting on May 28, 2014 at 10:00 a.m. PT. Besides, Illumina will participate in the upcoming Bank of America Merrill Lynch Global Technology Conference on June 3, 2014 at 4:20 p.m. PT at The Ritz-Carlton Hotel, San Francisco, California. The  full  analyst  notes  on  Illumina  are  available  to  download  free  of  charge  at:

http://www.analystsreview.com/2807-ILMN-22May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review